Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
Open Access
- 16 November 2021
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 2 (11) , 100446
Abstract
No abstract availableKeywords
Funding Information
- Kumamoto University
- Japan Society for the Promotion of Science (21K20935)
This publication has 36 references indexed in Scilit:
- Atypical angiopoietin-like protein that regulates ANGPTL3Proceedings of the National Academy of Sciences, 2012
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaNew England Journal of Medicine, 2010
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL)Journal of Biological Chemistry, 2009
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJAMA, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Angiopoietin-like proteins: potential new targets for metabolic syndrome therapyTrends in Molecular Medicine, 2005
- ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein LipaseJournal of Biological Chemistry, 2002
- Angptl3 regulates lipid metabolism in miceNature Genetics, 2002
- Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease riskAtherosclerosis, 1994